Xbrane Biopharma AB’s (publ.) (”Xbrane”) Year-end Report 2023, is as of today, available on the Company’s website, www.xbrane.com.
FINANCIAL OVERVIEW
FOURTH QUARTER 2023*
• Revenue amounted to
• Other operating income was
• EBITDA amounted to SEK –69.2 m (–50.7).
• R&D costs amounted to SEK –79.0 m (–59.5), corresponding to 84 percent (82) of total operating costs.
• The loss for the period was
• Earnings per share was SEK –5.28 (–2.25).
• Cash and cash equivalents at the end of the period amounted to
•
FINANCIAL OVERVIEW
FULL YEAR 2023*
• Revenue amounted to
• Other operating income was
• EBITDA amounted to SEK –288.4 m (–149.6).
• R&D costs amounted to SEK –305.8 m (–199.6), corresponding to 82 percent (82) of total operating costs.
• The loss for the period was
• Earnings per share was SEK –13.52 (–6.75).
• Cash and cash equivalents at the end of the period amounted to
•
*Figures in parentheses refer to the corresponding period of the previous year.
SIGNIFICANT EVENTS DURING
THE FOURTH QUARTER 2023**
• In November, it was announced that the company was focusing its development portfolio and ending the development of Xtrudane™ (biosimilar candidate for Keytruda®). A cost-saving scheme expected to generate approximately
• In December, it was announced that three new patents had been approved by the Swedish Intellectual Property Office (PRV).
SIGNIFICANT EVENTS
AFTER THE END OF THE QUARTER**
• In January, a rights issue of units worth around
**See page 8 for more information
Web cast
If you wish to participate via audiocast please use the link below. Via the audiocast you are able to ask written questions.
Teleconference
If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
Call Access (financialhearings.com)
© Modular Finance, source